Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.81 |
| ▸ | HPGD | P15428 | 4/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.81 |
| ▸ | RECQL | P46063 | 2/20 | 0.81 |
| ▸ | GALK1 | P51570 | 2/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.81 |
| ▸ | HBB | P68871 | 2/20 | 0.81 |
| ▸ | PIM1 | P11309 | 1/20 | 0.81 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.81 |
| ▸ | MAOA | P21397 | 5/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27462842 | 0.94 | MEN1 (0.76) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| Tricetin SCHEMBL158384 | 0.90 | MEN1 (1.00) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL20868306 | 0.86 | FTO (0.76) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL29576775 | 0.84 | MAOA (0.92) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL12378833 | 0.84 | MAOA (0.92) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL32679657 | 0.84 | MEN1 (0.82) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL13300950 | 0.83 | CYP1B1 (0.77) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL11981018 | 0.83 | CYP1B1 (0.77) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| SCHEMBL28112536 | 0.81 | MEN1 (0.64) | MEN1ALDH1A1MAPTKMT2ACYP3A4 | |
| Tricetin SCHEMBL4822637 | 0.80 | PTPRS (0.82) | MEN1ALDH1A1MAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020040831-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | PERLARA PBC (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | STEM CELL THERANOSTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2163619-A1 | ROSE CONTAINING FLAVONE AND MALVIDIN, AND METHOD FOR PRODUCTION THEREOF | International Flower Developments Proprietary Limited (AU) | 2010-03-17 | — | — | EP | disclosed |
| EP-2159283-A1 | ROSE CONTAINING FLAVONE, AND METHOD FOR PRODUCTION THEREOF | International Flower Developments Proprietary Limited (AU) | 2010-03-03 | — | — | EP | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885ALDH1A1 3621/4885MAPT 2788/4885 |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | RDX, TNNT2, CHLSN | MEN1 1453/4885ALDH1A1 2561/4885MAPT 4042/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885ALDH1A1 3621/4885MAPT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.